STOCK TITAN

Pyxis Oncology: BVF Partners reports about 9.99% ownership

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Pyxis Oncology, Inc. (PYXS) ownership amendment reports that, as of September 30, 2026, BVF Partners L.P., BVF Inc. and Mark N. Lampert may each be deemed to beneficially own the same 11,945,583 shares, approximately 9.99% of outstanding shares. BVF GP Holdings LLC may be deemed to beneficially own 10,859,497 shares, approximately 9.1%; these attributed positions overlap rather than representing separate blocks.

The reporting persons and a managed account held 7,840,062 Warrants exercisable at $3.289 per share, but the 9.99% ownership limit blocked exercise of all of them. The limit also restricted exercise of Pre-Funded Warrants to 119,443 of 1,185,922 underlying shares; a separate blocker prohibited exercise of all 6,723,600 Common Warrants, exercisable at $3.50 per share, as of September 30, 2026.

Shares attributed to BVF Partners L.P., BVF Inc. and Mark N. Lampert 11,945,583 shares Each may be deemed to beneficially own the same position as of September 30, 2026
Beneficial ownership percentage Approximately 9.99% Attributed to BVF Partners L.P., BVF Inc. and Mark N. Lampert as of September 30, 2026
Warrants 7,840,062 warrants Held by reporting persons and a managed account; exercise was blocked as of September 30, 2026
Warrant exercise price $3.289 per share Exercise price for the Warrants
Pre-Funded Warrant underlying shares 1,185,922 shares The blocker limited exercise to 119,443 shares as of September 30, 2026
Pre-Funded Warrant shares exercisable under blocker 119,443 shares As of September 30, 2026
Common Warrants 6,723,600 warrants Exercise was blocked as of September 30, 2026
Common Warrant exercise price $3.50 per share Exercise price for the Common Warrants
beneficial ownership financial
"Amount beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Maximum Percentage financial
"the "Maximum Percentage""
Pre-Funded Warrants Blocker financial
"the "Pre-Funded Warrants Blocker""
Common Warrants Blocker financial
"the "Common Warrants Blocker""
exercise price financial
"an exercise price per Share equal to $3.289"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
overall survival analysis medical
"results of the overall survival analysis for its Phase 1 monotherapy study"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PYXS shares may Mark N. Lampert be deemed to beneficially own?

Mark N. Lampert may be deemed to beneficially own 11,945,583 shares, approximately 9.99% of outstanding shares. The same position is also attributed to BVF Partners L.P. and BVF Inc., so these are overlapping attributions, not separate share blocks.

How many PYXS warrant shares could the reporting persons exercise?

As of September 30, 2026, the 9.99% blocker prohibited exercise of all 7,840,062 Warrants and all 6,723,600 Common Warrants. The Pre-Funded Warrants blocker limited exercise to 119,443 of 1,185,922 underlying shares.

When do PYXS Common Warrants expire?

The Common Warrants expire at 5:00 p.m. New York City time on the earlier of the fifth anniversary of November 13, 2026, or the 30th calendar day following the later of the Charter Amendment Effective Date and public disclosure of the results of the overall survival analysis for the Phase 1 MICVO monotherapy study, which is expected in the first half of 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





747324101

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BIOTECHNOLOGY VALUE FUND L P
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF I GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF II GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
Biotechnology Value Trading Fund OS LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF Partners OS Ltd.
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF GP HOLDINGS LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF PARTNERS L P/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF INC/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
LAMPERT MARK N
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert
Date:11/16/2026

Keep reading